Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Illumina

- PMLiVE

Imbruvica and Gazyvo approved in first non-chemo CLL use

Further boost for blockbuster leukaemia drug

- PMLiVE

Hardy returns to Genentech as CEO

In other news, Vertex fires chief operating officer

- PMLiVE

GSK and Sanofi join Finland’s 500,000 genomics study

AstraZeneca, MSD and Pfizer already participating

- PMLiVE

Chugai gains FDA breakthrough status for rare CNS treatment

Adds to company's BTD roll-call

- PMLiVE

Roche gains EU PRIME status for Spinraza rival

Oral treatment joins Novartis' gene therapy challenger

- PMLiVE

AZ and CRUK launch Cambridge genomics centre

New centre adds to Cambridge's biotech cluster

- PMLiVE

Roche’s O’Day swaps big pharma for big biotech

Move to Gilead enforces reshuffle at neighbours Genentech

- PMLiVE

Grail to initiate largest ever UK cancer screening study

Will start testing on 50,000 people in early 2019

Roche Basel Switzerland

Roche builds on Immunocore ImmTAC deal

Extends partnership to target MAGE-A4 protein tumours

- PMLiVE

Roche gains speedy review for Tecentriq in first-line breast cancer

Set to become the first immunotherapy for triple negative breast cancer

Roche Basel Switzerland

Roche and AbbVie prepare to move Venclexta into first-line CLL

Data shows an extended PFS compared to those on Gazyva plus chlorambucil chemo

- PMLiVE

Roche’s new flu pill Xofluza approved in US

First novel treatment in decades, but hasn't shown superiority to Tamiflu

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links